Peripheral artery disease (PAD) is a common atherosclerotic disorder with incomplete understanding of its molecular drivers. Epigenetic regulation, particularly DNA methylation, is influenced by known PAD risk factors such as aging, smoking, and metabolic disease, but genome-wide methylation signatures specifically associated with PAD remain understudied. Identifying methylation patterns linked to PAD could inform biomarker development and epigenetic-targeted interventions.
To characterize genome-wide blood DNA methylation patterns associated with clinically diagnosed peripheral artery disease (PAD) using the Illumina Infinium MethylationEPIC v2.0 platform and to identify enriched biological processes and pathways among implicated genes.
This investigation was a prospective, single-center pilot epigenome-wide association study (EWAS) conducted at an academic medical center. The study analyzed pooled whole-blood genomic DNA with pool-level bioinformatic processing.
Participants comprised 10 adults with clinically diagnosed PAD (mean age 72.7 ± 11.2 years; 50% female) and 22 age- and sex ratio–matched healthy controls (mean age 74.6 ± 7.8). Genome-wide methylation profiling was performed using the Illumina Infinium MethylationEPIC v2.0 BeadChip, covering over 935,000 CpG sites.
Raw array data passed quality control procedures and were processed with the SeSAMe pipeline. After QC, 933,942 probes were retained for analysis. Differentially methylated loci (DMLs) and differentially methylated regions (DMRs) were identified using thresholds of false discovery rate (FDR) ≤ 0.01 and absolute methylation difference |Δβ| ≥ 0.10. Enrichment analyses of genes supported by DMLs and DMRs were performed with clusterProfiler using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) computational tools.
Probe count and differential methylation
Following quality control, the analysis included 933,942 probes. The majority of significant DMLs were characterized by hypomethylation in PAD compared with controls. Applying the stated DML and DMR significance criteria and intersecting DML- and DMR-supported gene lists yielded a set of 16,854 high-confidence genes associated with differential methylation in PAD.
Functional enrichment (GO)
Gene Ontology overrepresentation among the implicated genes revealed strong enrichment for processes and molecular functions tied to muscle and developmental biology. Key GO terms included muscle system processes, regulation of membrane potential, embryonic organ development, DNA-binding transcription activator activity, actin binding, and metal ion transmembrane transporter activity. These terms point toward programs involved in contractile function, ion handling, transcriptional control, and cytoskeletal interactions.
Cellular component enrichment
Cellular component terms were dominated by structures relevant to cell movement and adhesion: cell leading edge, focal adhesion, and cell cortex. These enrichments align with modulation of cell motility and intercellular attachment mechanisms.
Pathway enrichment (KEGG)
KEGG pathway analysis identified pathways with established relevance to vascular biology and the behavior of vascular cells. Dominant pathways included calcium signaling, cadherin signaling, MAPK signaling, and cytoskeleton-related pathways in muscle cells. These pathways are implicated in endothelial function, vascular smooth muscle cell (VSMC) phenotypic switching, and pathological angiogenesis.
Interpretation of methylation pattern
Overall, blood DNA methylation patterns observed in this pilot cohort indicate enrichment of developmental vascular, muscle, and cell-motility programs. The authors interpret these signatures as reflective of biological programs that are reactivated in adult vascular pathology — for example, endothelial dysfunction, VSMC phenotypic modulation, and maladaptive angiogenic responses.
In this pilot EWAS of pooled whole-blood DNA from PAD patients and matched controls, the authors identified widespread methylation differences, predominantly hypomethylation, and implicated a large set of genes (16,854) enriched for muscle, developmental, adhesion, and signaling programs relevant to vascular disease. These results generate hypothesis-driven leads for peripheral blood biomarkers and potential epigenetic therapeutic targets in PAD. The study emphasizes the biological plausibility linking developmental programs and cytoskeletal/adhesion signaling with PAD pathophysiology.
As reported, this study is a small, single-center pilot using pooled DNA and pool-level bioinformatic analysis, which constrains individual-level resolution and limits assessment of confounders. The cohort size (10 PAD cases, 22 controls) and the preprint status mean results require cautious interpretation and independent validation. The authors explicitly call for larger, longitudinal, multi-ethnic studies to validate these methylation signatures, test their association with clinical outcomes, and explore their utility as biomarkers or therapeutic targets.
The study reports institutional review board approval from the Ethics committee/Institutional Review Board of Penn State College of Medicine (IRB Protocol Number 21252EP) and states that participant consent was obtained. The authors declare no competing interests. All data generated in the study are available from the authors upon reasonable request. The article is a medRxiv preprint and has not undergone peer review; it should not be used to guide clinical practice.